New England Journal of Medicine· 2020Q1

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Lisa A. Jackson, Evan J. Anderson, Nadine Rouphael, Paul C. Roberts et al.

3,490citations
Q1SCImago
2020year

Short summary

The mRNA-1273 vaccine candidate induced detectable antibody and neutralizing immune responses against SARS-CoV-2 in all 45 healthy adult participants in a Phase 1 trial, with higher doses correlating to stronger responses.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Infectious Diseases

Infectious DiseasesMedicine